Core Insights - Dover Corporation reported a revenue of 1.9billionforQ12025,adecreaseof1239 million, and diluted EPS from continuing operations also decreased by 60% to 1.73,primarilyduetoasignificantgainfromthedispositionofDe−Sta−Cointhepreviousyear[4][9]−Onanadjustedbasis,earningsfromcontinuingoperationsincreasedby18283 million, with adjusted diluted EPS rising by 19% to 2.05[4][19]FinancialPerformance−RevenuebreakdownforQ12025showedadeclineinEngineeredProductsby23.58.04 to 8.24,withadjustedEPSprojectedbetween9.20 and $9.40 [9][32] Management Commentary - The CEO highlighted encouraging results with favorable book-to-bill ratios across all segments and noted strong demand in biopharma components, thermal connectors, and CO2 systems [6][7] - The company is well-positioned in a dynamic global trading environment, leveraging agile business models and manageable supply chains [8][9] - Dover's strategy includes a focus on preserving profitability and responding flexibly to macroeconomic changes, as demonstrated during the pandemic [9][10] Guidance and Outlook - For Q1 2025, Dover reported a backlog that supports a majority of its second-quarter revenue, indicating strong future performance [7][9] - The company anticipates full-year revenue growth of 2% to 4%, both on an all-in and organic basis [9][32] - The adjusted earnings guidance reflects confidence in operational execution and capital deployment strategies [9][32]
Dover(DOV) Prnewswire·2025-04-24 10:30